Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 16.06
(1.58%)
CNY 16.06
(1.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 19.52 Million CNY | -49.8% |
| 2022 | 38.9 Million CNY | -37.96% |
| 2021 | 62.71 Million CNY | 9.44% |
| 2020 | 57.3 Million CNY | -28.1% |
| 2019 | 79.69 Million CNY | 1.74% |
| 2018 | 78.33 Million CNY | 41.88% |
| 2017 | 55.2 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -17.08 Million CNY | -77.44% |
| 2024 Q1 | 2.23 Million CNY | -49.71% |
| 2024 Q2 | -9.62 Million CNY | -530.69% |
| 2023 FY | 19.52 Million CNY | -49.8% |
| 2023 Q3 | 4.09 Million CNY | -65.86% |
| 2023 Q4 | 4.44 Million CNY | 8.64% |
| 2023 Q1 | -988.97 Thousand CNY | 63.52% |
| 2023 Q2 | 11.98 Million CNY | 1311.68% |
| 2022 Q2 | 14.98 Million CNY | 7.0% |
| 2022 Q1 | 14 Million CNY | 40.0% |
| 2022 FY | 38.9 Million CNY | -37.96% |
| 2022 Q4 | -2.71 Million CNY | -121.48% |
| 2022 Q3 | 12.62 Million CNY | -15.75% |
| 2021 Q1 | 17.65 Million CNY | -25.86% |
| 2021 FY | 62.71 Million CNY | 9.44% |
| 2021 Q4 | 10 Million CNY | -15.78% |
| 2021 Q3 | 11.87 Million CNY | -48.75% |
| 2021 Q2 | 23.17 Million CNY | 31.33% |
| 2020 Q4 | 23.8 Million CNY | 59.73% |
| 2020 Q3 | 14.9 Million CNY | -28.23% |
| 2020 Q2 | 20.76 Million CNY | 1052.88% |
| 2020 Q1 | -2.17 Million CNY | -119.35% |
| 2020 FY | 57.3 Million CNY | -28.1% |
| 2019 Q4 | 11.26 Million CNY | 0.0% |
| 2019 FY | 79.69 Million CNY | 1.74% |
| 2018 FY | 78.33 Million CNY | 41.88% |
| 2017 FY | 55.2 Million CNY | 0.0% |